Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

TGen and Scottsdale Healthcare discover new 'pathways'

09.10.2009
Computer simulations validate treatment targets for lung cancer

Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.

Dr. Glen Weiss, Director of Thoracic Oncology at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare, said the study showed the value of conducting computer modeling, or "in silico" research.

TCRS is a partnership of TGen and Scottsdale Healthcare. The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific cancer targets.

Researchers hope that over time in silico research will help lower health care costs while speeding up the process of turning scientific discoveries into treatments for patients.

"There are pathways that you can identify just from an in silico analysis. And we can use these types of tools to explore treatments for patients, down the road,'' said Dr. Weiss, an Associate Investigator in TGen's Cancer and Cell Biology Division and the senior author of the paper, which will appear in print in JTO's November edition.

The study sought to identify metabolic pathways — a series of chemical reactions occurring within a cell — that could be targeted by drugs in patients with both small-cell and large-cell lung cancers. Small-cell lung cancer represents about 15 percent of all lung cancers. The rest are classified as non-small cell lung cancer, of which large-cell lung cancer represents about 10 percent.

The study used publicly available data sets, searching for connections that may have been previously overlooked.

"Within those datasets, there are common pathways. We point out some examples that provide some proof-of-principle from the in silico search,'' said Dr. Weiss, who was joined in his research by TGen's Dr. Chris Kingsley and by Dr. Anoor Paripati of the Scottsdale Clinical Research Institute at Scottsdale Healthcare.

As an example, the study cites one particular signaling pathway, Wnt/ß-catenin, that could be targeted by two drugs, vorinostat and dasatinib, both of which are under study in clinical trials.

"This is an exploration of the publicly available data sets in an attempt to answer a new question. It shows that you can look at pathways and identify targets. We did our validation by looking at what's been tested, or what's available already,'' Dr. Weiss said.

In silico research, which is far less costly than conducting genetic profiling analysis of cancer tumors, will become more common as the National Cancer Institute ramps up its cancer Biomedical Informatics Grid, also known as caBIG.

Such in silico research should lead to targets for further laboratory and clinical research, and also should help clinicians provide more personalized treatment for patients, Dr. Weiss said.

"There is going to be a wealth of profiling data out there in the near future. You can then apply techniques like this, and hopefully design smarter clinical trials to find the drugs that would work,'' Dr. Weiss said.

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, please visit: www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org
About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers diagnosis, treatment, research, prevention and support in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S. Groundbreaking cancer research is conducted through its Scottsdale Clinical Research Institute and TGen Clinical Research Service. Scottsdale Healthcare is the not-for-profit parent organization of the Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Osborn Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center, Scottsdale Clinical Research Institute and Scottsdale Healthcare Foundation. For additional information, please visit www.shc.org.
Press Contact:
Keith Jones, Director of Public Relations
Virginia G. Piper Cancer Center at Scottsdale Healthcare
480-882-4412
kjones@shc.org

Steve Yozwiak | EurekAlert!
Further information:
http://www.tgen.org

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>